Adocia (ADOCY) Stock Price, News & Analysis

Company Overview

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Key Stats

• Today's Range: $11.80 to $11.80
• 50-Day Range: $11.80 to $11.80
• 52-Week Range: $9.80 to $11.80
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $213.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADOCY Stock Analysis - Frequently Asked Questions

How have ADOCY shares performed this year?

Adocia's stock was trading at $11.80 on January 1st, 2025. Since then, ADOCY stock has increased by 0.0% and is now trading at $11.80.
View the best growth stocks for 2025 here.

How do I buy shares of Adocia?

Shares of ADOCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ADOCY
• CIK: N/A
• Web: www.adocia.com
• Phone: 33-04-72-61-06-10
• Fax: 33-04-72-36-39-67
• Employees: 78
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.55 million
• Price / Sales: 32.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,090,000
• Free Float: N/A
• Market Cap: $213.46 million
• Optionable: Not Optionable
• Beta: -0.12